Fruquintinib
Advanced Malignant Solid Tumor of Digestive System
Peking UniversitySmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Advanced Malignant Solid Tumor of Digestive System cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Toripalimab Peking University | Early Phase 1 | C |
Idov-Safetm Peking University | Early Phase 1 | C |
Same molecule, other indications
Fruquintinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →